公开(公告)号：WO1994029725A1

公开(公告)日：1994-12-22

申请号：PCT/EP1994001834

申请日：1994-06-06

Applicant: ABBOTT LABORATORIES ,  SIMPSON, Barry ,  GÜLTEKIN, Halil ,  MICHEL, Gerd ,  SUTHERLAND, Ranald

Inventor： ABBOTT LABORATORIES

IPC: G01N33/558

CPC classification number: G01N33/54306 ,  G01N33/56988

Abstract: An improved Western blot method wherein the captured antibody of a test sample is detected by a probe specific for the captured antibody. The capture reagent can be a lysate, a recombinant protein or a synthetic peptide specific for the antibody to be detected. A test kit for performing the method also is provided.

Abstract translation: 一种改进的Western印迹方法，其中通过对所捕获的抗体特异的探针检测测试样品的捕获的抗体。 捕获试剂可以是裂解物，重组蛋白质或对待检测抗体特异的合成肽。 还提供了用于执行该方法的测试工具包。

公开(公告)号：WO1994027656A1

公开(公告)日：1994-12-08

申请号：PCT/US1994005221

申请日：1994-05-11

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GOLDHARDT, Donald, Jay ,  HIRSCH, William, Henry

IPC: A61M01/00

CPC classification number: A61J15/0038 ,  A61J15/0015 ,  A61J15/0065 ,  A61J15/0092 ,  A61M2025/0233

Abstract: A gastrostomy tube (30) combines a conventional dome (34) and tubular shaft (31) with one-way cross-slit duckbill valve (44). The one-way cross-slit valve is made of an elastomeric material and has a hollow cylindrical body with first and second ends and an axis and a passageway through the body, the passageway being entirely intercepted by a ridge and valley wall or web structure integrally joined to the cylindrical body.

Abstract translation: 胃造口管（30）将传统的圆顶（34）和管状轴（31）与单向十字切口鸭嘴阀（44）组合。 单向交叉狭缝阀由弹性体材料制成并且具有中空的圆柱体，其具有第一和第二端以及穿过主体的轴线和通道，该通道被整体地被脊部和谷壁结构或网状结构整体拦截 连接到圆柱体。

公开(公告)号：WO1994026264A1

公开(公告)日：1994-11-24

申请号：PCT/US1994005341

申请日：1994-05-12

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  DELLARIA, Joseph, F. ,  BASHA, Anwer ,  BLACK, Lawrence, A. ,  CHERNESKY, Linda, J. ,  LEE, Wendy

IPC: A61K31/335

CPC classification number: C07D405/12 ,  C07D309/12

Abstract: Compounds of structure (I), wherein W is selected from (a), and (b), where Q is oxygen or sulfur, R and R are hydrogen or alkyl, or R and R , together with the nitrogen atoms to which they are attached, define a radical of formula (II) or (III), R is selected from hydrogen, alkyl, haloalkyl, optionally substituted phenyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, (alkoxycarbonyl)alkyl, and (alkylaminocarbonyl)alkyl; Z is -CH2-, oxygen, sulfur, or -NR where R is hydrogen or alkyl, L and L are selected from a valence bond, alkylene, propenylene, and propynylene, R , R , R , and R are independently selected from alkyl, haloalkyl, halogen, cyano, amino, alkoxycarbonyl, and dialkylaminocarbonyl, Y is selected from oxygen, -NR , where R is hydrogen or alkyl, and (c), where n = 0, 1, or 2, and R is alkyl, inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.

Abstract translation: 其中W选自（a）和（b）中的结构（I）的化合物，其中Q是氧或硫，R 6和R 7是氢或烷基，或R 6和R 6， （II）或（III）的基团，其中R 8与它们所连接的氮原子一起定义为式（II）或（III）的基团，R 8选自氢，烷基，卤代烷基，任选取代的苯基，羟基烷基，氨基烷基，羧基烷基， （烷氧基羰基）烷基和（烷基氨基羰基）烷基; Z是-CH 2 - ，氧，硫或-NR 9，其中R 9是氢或烷基，L 1和L 2选自价键，亚烷基，亚丙烯基和亚丙炔基，R R 1，R 2，R 3和R 4独立地选自烷基，卤代烷基，卤素，氰基，氨基，烷氧基羰基和二烷基氨基羰基，Y选自氧，-NR 10， 其中R 10是氢或烷基，和（c）其中n = 0,1或2，R 5是烷基，抑制白细胞三烯的生物合成。 这些化合物可用于治疗或改善过敏性和炎性疾病状态。

公开(公告)号：WO1994024568A1

公开(公告)日：1994-10-27

申请号：PCT/US1993003749

申请日：1993-04-20

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  GRENIER, Frank, C. ,  LUCZKIW, Julie, A. ,  BERGMANN, Merry, E. ,  BLONSKI, David, R.

IPC: G01N33/96

CPC classification number: G01N33/9493 ,  G01N33/96 ,  Y10T436/10 ,  Y10T436/101666 ,  Y10T436/107497 ,  Y10T436/108331

Abstract: Disclosed is a stabilized, aqueous composition containing FK506. FK506 degrades rapidly in most aqueous matrices. The rate of degradation is decreased in the presence of blood cells or fragments of blood cells from human or animal sources. A number of matrices using blood components are possible. Blood can be used directly or the blood cells can be lysed. The blood is diluted with a solution of an alkali halide.

Abstract translation: 公开了含有FK506的稳定的含水组合物。 FK506在大多数水性基质中迅速降解。 在存在来自人或动物来源的血细胞或血细胞片段的情况下，降解速率降低。 使用血液成分的多个矩阵是可能的。 可以直接使用血液，也可以将血液细胞裂解。 用碱性卤化物溶液稀释血液。

公开(公告)号：WO1994024311A1

公开(公告)日：1994-10-27

申请号：PCT/US1994004113

申请日：1994-04-13

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BACKMAN, Keith, C. ,  CARRINO, John, J. ,  SHIMER, George, H. ,  YOCUM, Robert, R.

IPC: C12Q01/68

CPC classification number: C07H21/00 ,  C12N9/22 ,  C12Q1/34 ,  C12Q1/6848 ,  C12Q1/6862 ,  C12Q2525/186 ,  C12Q2525/119 ,  C12Q2521/301

Abstract: The present invention involves methods of improving the Ligase Chain Reaction (LCR ) amplification schemes by modifying at least one probe end so that the probability of the probe contributing to spurious ligation and signal development is greatly reduced. Only after specific hybridization of the modified probe with true target are the modified ends "corrected" by endonuclease IV in a target dependent fashion to allow participation of the probe in the enzymatic ligation reaction. Specific modifications include 3' phosphate blocking groups and nucleic acid overhangs containing an abasic site at the point of ligation. Further embodiments include probes modified to contain ribonucleotide moieties which, after amplification, can be cleaved by RNase to destroy the amplification products and reduce the risk of contamination.

Abstract translation: 本发明涉及通过修饰至少一个探针末端来改进连接酶链反应（LCR TM）扩增方案的方法，从而大大减少了引起假结扎和信号发育的探针的概率。 只有经修饰的探针与真实靶标的特异性杂交后，修饰的末端以目标依赖的方式被核酸内切酶IV“校正”，以允许探针参与酶连接反应。 具体的修饰包括3'磷酸封闭基团和在连接点含有无碱基位点的核酸突出端。 其他实施方案包括经修饰以含有核糖核苷酸部分的探针，其扩增后可被RNA酶切割以破坏扩增产物并降低污染的风险。

公开(公告)号：WO1994021634A1

公开(公告)日：1994-09-29

申请号：PCT/US1994002683

申请日：1994-03-11

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  LULY, Jay, R. ,  KAWAI, Megumi

IPC: C07D471/16

CPC classification number: C07D498/18

Abstract: Compounds having formula (I), and the pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R and R is hydrogen, and the other of R and R is a radical having formula (II), as well as pharmaceutically compositions containing such compounds and methods of immunomodulative therapy utilizing the same.

Abstract translation: 具有式（I）的化合物及其药学上可接受的盐，酯，酰胺和前药，其中R 104和R 105中的一个为氢，R 104和R 105中的另一个为 具有式（II）的基团，以及含有这些化合物的药物组合物和利用其的免疫调节治疗方法。

公开(公告)号：WO1994021258A1

公开(公告)日：1994-09-29

申请号：PCT/US1994002741

申请日：1994-03-14

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  KAWAI, Megumi ,  OR, Yat, Sun ,  LULY, Jay, R.

IPC: A61K31/445

CPC classification number: C07D498/18

Abstract: Immunomodulatory macrocyclic compounds having formula (I), and pharmaceutically acceptable salts, esters, amides and prodrugs thereof, wherein one of R , R , R and R is a radical having formula (II), (III) or (IV), as well as pharmaceutically compositions containing such compounds and methods of immunomodulatory therapy utilizing the same.

Abstract translation: 具有式（I）的免疫调节大环化合物及其药学上可接受的盐，酯，酰胺和前药，其中R 107，R 108，R 109和R 110之一是具有式（II）的基团 ），（III）或（IV），以及含有这些化合物的药物组合物和利用其的免疫调节治疗方法。

公开(公告)号：WO1994020636A1

公开(公告)日：1994-09-15

申请号：PCT/US1994002539

申请日：1994-03-09

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  BRATE, Elaine, M. ,  BRENNAN, Catherine, A. ,  BRIDON, Dominique, P. ,  JAFFE, Keeve, D. ,  KRAFFT, Grant, A. ,  MANDECKI, Wlodzimierz ,  MARCH, Steven, C. ,  RUSSELL, John, C. ,  YUE, Vincent, T.

IPC: C12Q01/00

CPC classification number: C07K14/59 ,  C07K2319/40 ,  C12N9/16 ,  C12Q1/42

Abstract: This invention relates to genetically engineered enzymes, their ligand conjugates, their manufacture, and their use in qualitative or quantitative assays. A hybrid enzyme, such as an AP-epitope, has a foreign amino acid moiety (an epitope) inserted near the active site of the starting AP enzyme. The foreign amino acid moiety binds with an analyte, and, as a consequence of this binding, the enzymatic activity of the hybrid enzyme, AP-epitope, is modified. The changes in the enzymatic activity are dependent upon the presence, or the amount, of the analyte. In another embodiment, the hybrid enzyme consists of a cysteine introduced near the active site of an AP to give a hybrid enzyme. The cysteine on the hybrid enzyme serves as a point of conjugation of a ligand, such as theophylline, ferritin, thyroxine, or digoxigenin, to form the hybrid enzyme-ligand conjugate. The ligand binds with an antibody, an analyte or a binding molecule to an analyte and as a result of this binding, the enzymatic activity of the hybrid enzyme-ligand conjugate is modified or modulated.

Abstract translation: 本发明涉及基因工程改造的酶，其配体缀合物，其制备及其在定性或定量测定中的用途。 诸如AP-表位的杂交酶在起始AP酶的活性位点附近插入外源氨基酸部分（表位）。 外来氨基酸部分与分析物结合，并且作为该结合的结果，修饰了杂合酶AP-表位的酶活性。 酶活性的变化取决于分析物的存在或数量。 在另一个实施方案中，杂交酶由在AP的活性位点附近引入的半胱氨酸组成以产生杂交酶。 杂交酶上的半胱氨酸用作配体如茶碱，铁蛋白，甲状腺素或地高辛的缀合点，以形成杂交酶 - 配体缀合物。 配体与分析物结合抗体，分析物或结合分子，作为该结合的结果，修饰或调节杂交酶 - 配体结合物的酶活性。

公开(公告)号：WO1994020464A1

公开(公告)日：1994-09-15

申请号：PCT/US1994001975

申请日：1994-02-22

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  CHANG, Chi-Deu

IPC: C07D207/40

CPC classification number: C07D207/404 ,  C07D207/416 ,  C07D451/12 ,  G01N33/54353

Abstract: The instant invention is a method of coupling compounds comprising the septs of: a) forming a maleimide derivative by reacting a maleimide containing compound having formula (I) with an amine functional compound capable of displacing the N-hydroxysuccinimide group; and b) reacting the derived maleimide of step (a) with a second amine functional compound.

Abstract translation: 本发明是一种偶联化合物的方法，该方法包括：a）通过使具有式（I）的含马来酰亚胺化合物与能够置换N-羟基琥珀酰亚胺基团的胺官能化合物反应形成马来酰亚胺衍生物; 和b）将得自步骤（a）的马来酰亚胺与第二种胺官能化合物反应。

公开(公告)号：WO1994019332A1

公开(公告)日：1994-09-01

申请号：PCT/US1994001457

申请日：1994-02-08

Applicant: ABBOTT LABORATORIES

Inventor： ABBOTT LABORATORIES ,  NORBECK, Daniel, W. ,  SHAM, Hing, Leung ,  KEMPF, Dale, J. ,  ZHAO, Chen

IPC: C07D263/34

CPC classification number: C07D213/30 ,  C07C281/02 ,  C07C281/06 ,  C07C2601/14 ,  C07D213/38 ,  C07D213/40 ,  C07D261/08 ,  C07D263/32 ,  C07D265/30 ,  C07D275/02 ,  C07D277/24 ,  C07D277/28 ,  C07D307/52 ,  C07D309/04 ,  C07D405/12 ,  C07D413/12 ,  C07D417/12

Abstract: A retroviral protease inhibiting compound of formula (I) is disclosed.

Abstract translation: 公开了式（I）的逆转录病毒蛋白酶抑制化合物。